| Not Yet Recruiting | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients Wit NCT07416695 | Shanghai Henlius Biotech | Phase 1 |
| Recruiting | Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC NCT07110103 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Active Not Recruiting | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms NCT07145333 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Phase 2 / Phase 3 |
| Recruiting | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer NCT07508852 | Peking University First Hospital | Phase 1 / Phase 2 |
| Recruiting | SLV-154 Treatment of Metastatic Solid Tumors NCT06771219 | Solve Therapeutics | Phase 1 |
| Not Yet Recruiting | Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Pros NCT06820762 | The Second Affiliated Hospital of Dalian Medical University | Phase 2 |
| Recruiting | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors NCT06657222 | Tubulis GmbH | Phase 1 / Phase 2 |
| Recruiting | PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung C NCT06616532 | Biotheus Inc. | Phase 3 |
| Recruiting | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study NCT06534762 | Zhejiang Provincial People's Hospital | Phase 2 |
| Not Yet Recruiting | Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell NCT06441344 | Taizhou Hospital | Phase 3 |
| Recruiting | Adebrelimab + Apatinib in SCLC Maintenance Therapy NCT06475209 | Tang-Du Hospital | Phase 2 |
| Recruiting | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer NCT06179069 | Zai Lab (Shanghai) Co., Ltd. | Phase 1 |
| Recruiting | Cognitive Screening in Lung Cancer Patients NCT06727370 | European Institute of Oncology | — |
| Recruiting | Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) NCT06116019 | Charite University, Berlin, Germany | — |
| Suspended | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer NCT05903092 | Hirva Mamdani | Phase 2 |
| Withdrawn | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer NCT05655598 | Brown University | Phase 1 |
| Recruiting | Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection NCT06021483 | Boryung Pharmaceutical Co., Ltd | — |
| Active Not Recruiting | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunother NCT05703269 | Wake Forest University Health Sciences | N/A |
| Active Not Recruiting | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC NCT05844150 | Biotheus Inc. | Phase 2 |
| Recruiting | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 NCT05130255 | Y-mAbs Therapeutics | Phase 1 |
| Active Not Recruiting | Study of Oral MRT-2359 in Selected Cancer Patients NCT05546268 | Monte Rosa Therapeutics, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC NCT05879068 | Biotheus Inc. | Phase 2 |
| Withdrawn | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab NCT04677361 | Fox Chase Cancer Center | EARLY_Phase 1 |
| Recruiting | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small NCT04826341 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage S NCT05026593 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Terminated | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer NCT04750239 | Y-mAbs Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Ca NCT04802174 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors NCT04686682 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Unknown | Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer NCT04684017 | Shanghai Chest Hospital | Phase 2 |
| Completed | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] NCT03428607 | Samsung Medical Center | Phase 2 |
| Completed | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer NCT03575793 | Salma Sabbour | Phase 1 / Phase 2 |
| Completed | Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases NCT03297788 | Juergen Debus | N/A |
| Unknown | Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment NCT03244904 | Fujian Cancer Hospital | — |
| Completed | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors NCT02611024 | PharmaMar | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. NCT02734004 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC NCT02990780 | Shanghai Chest Hospital | Phase 3 |
| Terminated | A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advan NCT02109016 | Clovis Oncology, Inc. | Phase 2 |
| Completed | Pazopanib Maintenance for SCLC NCT01797874 | Samsung Medical Center | Phase 2 |
| Terminated | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection NCT01829971 | Mirna Therapeutics, Inc. | Phase 1 |
| Completed | Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer NCT01797159 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Pazopanib in Relapsed and Refractory Small Cell Lung Cancer NCT01713296 | Hellenic Oncology Research Group | Phase 2 |
| Completed | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer NCT01253369 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation NCT00522639 | Maastricht Radiation Oncology | Phase 3 |
| Terminated | A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy NCT00447421 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer NCT00046787 | Astellas Pharma Inc | Phase 2 |
| Completed | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors NCT00346385 | ImmunoGen, Inc. | Phase 1 |
| Temporarily Not Available | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer NCT07535359 | Daiichi Sankyo | — |